

European Journal of Chemistry

Journal homepage: www.eurjchem.com

Cyclocondensation, antimicrobial activity and semi-empirical AM1-M0 calculations of benzopyrone derivatives

Hafez Mohamed El-Shaaer

Department of Chemistry, Faculty of Education, Ain Shams University, Roxy, 11711, Cairo, Egypt

*Corresponding author at: Department of Chemistry, Faculty of Education, Ain Shams University, Roxy, 11711, Cairo, Egypt. Tel.: +201.12627069; fax: +202.2581243. E-mail address: <u>elshaaer@hotmail.com</u> (H.M. El-Shaaer).

ARTICLE INFORMATION

Received: 13 August 2011 Received in revised form: 06 September 2011 Accepted: 22 September 2011 Online: 31 March 2012

KEYWORDS

Synthesis Benzopyrone 4-Quinolinone Cyclocondensation AM1-MO calculation Antimicrobial activity

1. Introduction

ABSTRACT

An efficient synthesis of 7-amino-9-hydroxy-6-oxo-6H-benzo[c]chromene-8-carbonitrile derivatives (**2**,**6**) and 4-methyl-2-oxo-2H-chromene-3-carbonitrile (**5**) via Claisen condensation of 2-hydroxyacetophenones (**1**,**3**) with ethyl cyanoacetate in the presence of sodium metal is reported. Reaction of **5** with thiosemicarbazide gave 1-(3-cyano-4-methyl-2-oxoquinolin-1(2H)-yl)thiourea (**7**). Treatment of **5** with 6,8-dichloro-4-oxo-4H-chromene-3-carboxaldehyde gave 4-(2-(6,8-dichloro-4-oxo-4H-chromen-3-yl)-2-hydroxyethyl)-2-oxo-2H-chromene-3-carbonitrile (**9**). Further treatment of **5** with ethyl acetate followed by condensation with 6,8-dichloro-3-formylchromone gave 7-((6,8-dichloro-4-oxo-4H-chromen-3-yl)methyleneamino)-9-hydroxy-6H-benzo[c]chromen-6-one (**12**). Structures of the products were established on the basis of elemental analysis, IR, ¹H and ¹³C NMR, mass spectra and semi-empirical AM1-MO calculations. The antimicrobial activities of the synthesized products were also studied.

Fused coumarins (2*H*-1-benzopyran-2-ones) comprise a very interesting class of compounds due to their significant antibacterial [1] and pharmacological activities [2]. Also, chromone (4H-1-benzopyran-4-one) derivatives exhibit significant biological activities, such as antifungal [3,4], antimycobacterial [5,6], antialergic [7], antitumour [8-10], and antiviral [11-12]. So, and with the expectative to find biological activity, I decided to investigate the synthesis of some novel systems of coumarin derivatives bearing chromone moiety. Recently, the synthesis [13], photochemical [14] and theoretical [15] properties of chromone derivatives were largely investigated.

The aim of the present paper is to investigate an efficient synthesis of coumarin derivatives containing active methyl and cyano groups and study their cyclocondensation reactions with ethyl cyanoacetate, thiosemicarbazide, ethyl acetate and 6,8-dichloro-4-oxo-4*H*-chromene-3-carboxaldehyde. The antimicrobial activities for the prepared compounds were investigated. Also, semi-empirical AM1 and Ab Initio (STO-3G) molecular orbital calculations for the new compounds were studied and compared with their experimental data.

2. Experimental

2.1. Instrumentation

The uncorrected melting points were determined in an open capillary tube on a digital Stuart SMP-3 apparatus. $^{1}H/^{13}C$ NMR spectra were obtained on a 500/125 MHz Jeol Eca or on a 300/75.46 MHz Varian Mercury VX-300 NMR spectrometer in DMSO- d_6 with tetramethylsilane as an internal standard. Elemental analyses were performed on Vario El Elementar apparatus. IR spectra were recorded on FTIR Nicolet IS10

spectrophotometer (cm⁻¹), using KBr disks. Mass spectra were recorded on a Gas Chromatographic GCMSqp 1000 ex Shimadzu instrument at 70 eV. Thermodynamic data were obtained from molecular mechanical calculations on the basis of the semi-empirical AM1 and Ab Initio (STO-3G) methods with the HyperChem 8.03 computer program.


2.2. Synthesis


6,8-Dichloro-4-oxo-4*H*-chromene-3-carboxaldehyde (8) was prepared according to [15]. The other chemicals were purchased from the suppliers as the highest purity grade.

2.2.1. 7-Amino-2,4-dichloro-9-hydroxy-6-oxo-6H-benzo[c] chromene-8-carbonitrile (2)

A solution of 3,5-dichloro-2-hydroxyacetophenone (1) (4.0 g, 2 mmol) in ethyl cyanoacetate (22 cm^3), sodium metal (2 g, 8 mmol) was added by small portion on the solution and the reaction mixture was heated on water-bath for 2 h and then heated under reflux for 1 h. The product was treated with water and acidified with acetic acid. The solid obtained was filtered, and crystallized from acetic acid to give 2 as yellow crystals (Scheme 1).

7-Amino-2,4-dichloro-9-hydroxy-6-oxo-6H-benzo[c]chrome ne-8-carbonitrile (2): Yield: 29%. M.p.: 270-272 °C. FT-IR (KBr, cm⁻¹): 3350, 3260, 3197, 3064, 2981, 2209, 1736, 1682, 1616. ¹H NMR (300 MHz, DMSO-*d*₆): 2.50 (m, 3H, C*H*, *CH*₂), 4.19 (m, 2H, NH₂, exchangeable with D₂O), 8.02-8.09 (m, 2H, H-1 and H-3), 8.88 (s, 1H, exchangeable with D₂O), 9.19 (s, 1H, exchangeable with D₂O). ¹³C NMR (75.46 MHz, DMSO-*d*₆): 600, 72.0, 109.2, 117.5, 120.7, 120.9, 121.4, 122.3, 125.1, 129.1, 132.5, 146.6, 150.4, 155.8, 163.2, 166.1. MS (EI, m/z (%)): 322.4 (M+1, 15.9), 322.8 (M+2, 18.2).





Scheme 2

Anal. calcd. for $C_{14}H_6Cl_2N_2O_3$: C, 52.36; H, 1.88; N, 8.72. Found: C, 52.54; H, 2.00, N, 8.72%.

2.2.2. 4-Methyl-2-oxo-2H-chromene-3-carbonitrile (5) and 7amino-9-hydroxy-6-oxo-6H-benzo[c]chromene-8carbonitrile (6)

Method A: Sodium metal (10 g, 43 mmol) was added in small portion to a solution of 2-hydroxyacetophenone (3) (20.0 g, 15 mmol) in ethyl cyanoacetate (110 cm³). The reaction mixture was heated on water-bath for 3 h, and then cooled to room temperature, treated with ethanol (30 cm³) and refluxed for 1 h. The solid obtained was filtered, and crystallized from cyclohexane to give **5** as yellow crystals, Yield: 20%. M.p.: 192-194 °C (Scheme 2 and 3). The ethanolic filtrate was concentrated to its half amount, acidified with 96% acetic acid and diluted with water to give **6** as pall-yellow crystals, Yield: 30%. M.p.: 237-238 °C (acetic acid).

4-*Methyl-2-oxo-2H-chromene-3-carbonitrile* (**5**): FT-IR (KBr, cm⁻¹): 3060, 2920, 2228, 1723, 1600. ¹H NMR (500 MHz, DMSO*d*₆): 2.69 (s, 3H, *CH*₃), 7.44-7.47 (m, 2H, *H*-6 and *H*-8), 7.76 (t, *J* = 7.65 Hz, 1H, *H*-7), 7.95 (d, *J* = 8.45 Hz, 1H, *H*-5). ¹³C NMR (125 MHz, DMSO-*d*₆): 18.7 (-), 101.8 (quat), 114.8 (quat), 117.5 (+), 118.6 (quat), 125.8 (+), 127.6 (+), 135.8 (+), 153.2 (quat), 157.3 (quat), 164.2 (quat). MS (EI, m/z (%)): 184 (M-1, 13.7), 185 (M, 100.0), 186 (M+1, 12.1). Anal. calcd. for C₁₁H₇NO₂: C, 71.35; H, 3.81; N, 7.56. Found: C, 71.70; H, 3.50; N, 7.76%.

7-amino-9-hydroxy-6-oxo-6H-benzo[c]chromene-8-carbonitrile (6): FT-IR (KBr, cm⁻¹): 3370, 3282, 3220, 3079, 2987, 2211, 1705, 1638, 1609. ¹H NMR (300 MHz, DMSO-*d*₆): 2.47 (m, 3H, *CH*, *CH*₂), 4.22 (m, 2H, *NH*₂, exchangeable with D₂O), 7.43-7.49 (m, 2H, *H*-2 and *H*-3), 7.72 (dd, *J* = 7.2, 1.2 Hz, 1H, *H*-4), 7.93 (dd, *J* = 9.0, 1.2 Hz, 1H, *H*-1), 9.00, (s, 1H,


exchangeable with D_2O), 9.26 (s, 1H, exchangeable with D_2O). ¹³C NMR (75.46 MHz, DMSO-*d*₆): 59.9, 72.1, 116.5, 117.7, 118.5, 121.0, 124.9, 126.2, 133.2, 151.0, 152.2, 157.1, 164.3, 166.4. MS (EI, m/z (%)): 252.5 (M, 5.1). Anal. calcd. for C₁₄H₈N₂O₃: 66.67; H, 3.20; N, 11.11. Found: C, 66.52; H, 3.00; N, 11.50%.

Method B: A solution of compound **5** (0.5 g, 0.27 mmol) in ethoxide (0.15 g sodium, 10 cm³ absolute ethanol), and then ethyl cyanoacetate (1.0 cm³) was added and the mixture was refluxed on water-bath for 2 h, cooled to room temperature and acidified with 96% acetic acid. The solid obtained was filtered, and crystallized from acetic acid to give **6** as pall-yellow crystals (Scheme 2). M.p.: 237-238 °C. Yield: 59%.


2.2.3. 1-(3-Cyano-4-methyl-2-oxoquinolin-1(2H)-yl)thiourea (7)

A mixture of compound **5** (0.25 g, 0.13 mmol) and thiosemicarbazide (0.15 g, 0.16 mmol) in pyridine (2 cm^3) was refluxed for 5 h. The solid obtained was filtered, and crystallized from ethanol to give **7** as orange crystals (Scheme 4 and 5).


1-(3-Cyano-4-methyl-2-oxoquinolin-1(2H)-yl)thiourea (7): Yield: 73%. M.p.: 186-187 °C. FT-IR (KBr, cm⁻¹): 3368, 3263, 3177, 3061, 2923, 2228, 1724, 1601. ¹H NMR (300 MHz, DMSOd₆): 2.73 (s, 3H, CH₃), 4.47 (s, 2H, NH₂, exchangeable with D₂O), 7.45-7.50 (m, 2H, H-6 and H-8), 7.77 (dd, J = 7.8, 1.8 Hz, 1H, H-5), 7.93 (dd, J = 7.8, 6.3 Hz, 1H, H-7), 8.55 (s, 1H, NH, exchangeable with D₂O). ¹³C NMR (75.46 MHz, DMSO-d₆): 18.1, 101.2, 114.1, 116.9, 118.0, 120.7, 125.2, 127.0, 135.2, 152.6, 156.6, 163.6. MS (EI, m/z (%)): 256 (M-2, 16.7), 257 (M-1, 16.7), 258 (M, 13.3). Anal. calcd. for C₁₂H₁₀N₄OS: C, 55.80; H, 3.90; N, 21.69; S, 12.41. Found: C, 55.59; H, 4.00; N, 21.20; S, 12.15%.



Scheme 3



Scheme 4



Scheme 5


2.2.4. 4-(2-(6,8-Dichloro-4-oxo-4H-chromen-3-yl)-2hydroxyethyl)-2-oxo-2H-chromene-3-carbonitrile (9)

Method A: A mixture of compound **5** (0.5 g, 0.27 mmol) and 6,8-dichloro-4-oxo-4*H*-chromene-3-carboxaldehyde (**8**) (0.66 g, 0.27 mmol) in dimethylformamide (10 cm³) was stirred at room temperature (25 °C) for 4 h, leave overnight, filtered off and crystallized from acetic acid to give **9** as a white crystals (Scheme 6).

4-(2-(6,8-Dichloro-4-oxo-4H-chromen-3-yl)-2-hydroxyethyl)-2-oxo-2H-chromene-3-carbonitrile (9): Yield: 60%. M.p.: 293-294 °C. FT-IR (KBr, cm⁻¹): 3743 (br), 3060, 2226, 1727, 1652. ¹H NMR (500 MHz, DMSO-d₆): 2.07 (d, *J* = 6.9 Hz, 2H, CH₂), 2.85 (br. s, 1H, CH), 7.39-7.52 (m, 2H, Ar-H), 7.80 (s, 1H, H-7), 7.94 (d, *J* = 8.4 Hz, 1H, Ar-H), 8.04 (s, 1H, H-5), 8.24 (dd, *J* = 9.95, 6.1 Hz, 1H, Ar-H), 9.08 (s, 1H, H-2), 10.05 (s, 1H, 0H). MS (EI, m/z (%)): 410 (M-H₂O, 43.3). Anal. calcd. for C₂₁H₁₁Cl₂NO₅: C, 58.90; H, 2.59; N, 3.27. Found: C, 58.75; H, 2.23; N, 3.56%. *Method B*: A mixture of compound **5** (0.5 g, 0.27 mmol) and 6,8-dichloro-4-oxo-4H-chromene-3-carboxaldehyde (**8**) (0.66 g, 0.27 mmol) in dimethylformamide (5 cm^3) was refluxed for 5 min. The solid obtained was filtered and purified in the same manner as in method A, Yield: 69%.

2.2.5. 7-((6,8-Dichloro-4-oxo-4H-chromen-3yl)methyleneamino)-9-hydroxy-6H-benzo[c]chromen-6-one (12)

A solution of compound **5** (0.5 g, 0.27 mmol) in ethoxide (0.15 g sodium, 10 cm³ absolute ethanol), and then ethyl acetate (1.0 cm³) was added and the mixture was refluxed on water-bath for 2 h, cooled to room temperature and filtered off. The solid obtained (0.27 g) was mixed with acetic acid (2.5 cm³), sodium acetate (0.3 g) and 6.8-dichloro-4-oxo-4H-chromene-3-carboxaldehyde (0.26 g, 0.1 mmol) and refluxed for 1 h, filtered off and crystallized from ethanol to give **12** as a pale orange crystals (Scheme 7).



7-((6,8-Dichloro-4-oxo-4H-chromen-3-yl)methyleneamino)-9-hydroxy-6H-benzo[c]chromen-6-one (12): Yield: 65%. M.p.: 183-184 °C. FT-IR (KBr, cm⁻¹): 3431 (br), 3075, 1716, 1653, 1602. ¹H NMR (500 MHz, DMSO- d_6): 6.69 (s, 1H, -CH=N), 7.25 (s, 1H, Ar-H), 7.37-7.43 (m, 2H, Ar-H), 7.63-7.72 (m, 3H, Ar-H), 7.96 (s, 1H, H-5), 8.02 (s, 1H, H-2), 8.16-8.22 (m, 1H, Ar-H), 8.92 (s, 1H, OH, exchangeable with D₂O). Anal. calcd. for C₂₃H₁₁Cl₂NO₅: C, 61.08; H, 2.45; N, 3.10. Found: C, 61.42; H, 2.15; N, 2.75%.

2.3. Antimicrobial activity

The newly synthesized compounds were screened against Gram-positive bacteria: *Staphylococcus aureus* (ATCC 25923) and *Bacillus subtilis* (ATCC 6635), Gram-negative bacteria: *Salmonella typhimurium* (ATCC 14028) and *Escherichia coli* (ATCC 25922), Yeast: *Candida albicans* (ATCC 10231) and Fungus: *Aspergillus fumigatus*. The standardized disc-agar diffusion method [16] was followed to determine the activity of the synthesized compounds against the tested microorganisms.

The tested compounds were dissolved in dimethyl formamide (DMF) solvent and prepared in two concentrations 2 and 1 mg/mL. The antibiotic chloramphencol was used as standard reference in the case of Gram-negative bacteria, Cephalothin was used as standard reference in the case of Gram-positive bacteria and Cycloheximide was used as standard reference in the case of standard reference in the case of yeasts and fungi.

3. Results and discussion

3.1. Chemistry

The Claisen condensation of 2-hydroxyacetophenone derivatives with ethyl acetate in the presence of sodium metal gave β -dicarbonyl compound derivatives which were cyclized under the effect of conc. sulfuric acid to give 2-methylchromone derivatives [15].

The novel and unexpected Claisen condensation of 3,5dichloro-2-hydroxyacetophenone (1) with excess of ethyl cyanoacetate in the presence of sodium metal gave 7-amino-2,4-dichloro-9-hydroxy-6-oxo-6*H*-benzo[c]chromene-8-carbonitrile (2) (Scheme 1), but when unsubstituted 2hydroxyacetophenone (3) reacted under the same condition gave a mixture of 4-methyl-2-oxo-2*H*-chromene-3-carbonitrile (5) (20%) and 7-amino-9-hydroxy-6-oxo-6*H*-benzo[*c*] chromene-8-carbonitrile (6) (30%). When compound 5 was reacted with ethyl cyanoacetate in the presence of sodium ethoxide gave compound (6) (59%) (Scheme 2). The formation of compounds **2** and **6** proceeded via α , β unsaturated ester derivatives (**4**), which can be cyclized under the effect of heat to give compound **5**, further Claisen condensation on active methyl group of compound **5** followed by nucleophilic cyclization gave compounds (**2**, **6**) (Scheme 3).

The Claisen condensation of 3,5-dichloro-2-hydroxyacetophenone (1) with ethyl cyanoacetate gave only cyclocondensation product $2a \rightleftharpoons 2b$, while unsubstituted 2hydroxyacetophenone (3) gave a mixture of condensation product 5 and cyclocondensation product $6a \rightleftharpoons 6b$ due to the thermodynamic stabilities of $2a \rightleftharpoons 2b$ than $6a \rightleftharpoons 6b$ (Table 1). Also, theoretical thermodynamic data obtained from semiempirical AM1-MO calculations shows that structure 2b is more stabilized than 2a and 6b than 6a (Table 1).


 Table 1. Calculated heat of formation of coumarin derivatives by semiempirical AM1-M0 method.

Compound	Heat of formation (kcal/mol)					
2a	-13.65					
2b	-43.63					
5	-2.51					
6a	-5.21					
6b	-34.77					
9	-72.45					
10	59.69					

The presence of cyano group in a 3-position of coumarin moiety facilitate the nucleophilic ring addition on C=O group followed by ring fission and recyclization, so the reaction of thiosemicarbazide with compound **5** in pyridine gave 1-(3-cyano-4-methyl-2-oxoquinolin-1(2*H*)-yl)thiourea (**7**) (Scheme **4**) and the mechanism of formation of compound **7** (Scheme **5**).

The reaction of compound **5** with 6,8-dichloro-4-oxo-4*H*-chromene-3-carboxaldehyde (**8**) in dimethylformamide at room temperature (25 °C) and/or reflux for 5 min gave addition product **9** rather than the condensation product **10**. The preferable formation of **9** rather than **10** seems to be due to the thermodynamic stabilities according to semi-empirical AM1 calculation data, where the ΔH°_{f} = -72.45 kcal/mol for **9** which is much more stabilized than ΔH°_{f} = 59.69 kcal/mol of **10** (Table **1**) and also for the presence of strong hydrogen bond between the C=0 and the OH groups of chromone moiety of compound **9** (Scheme **6**).

The Claisen condensation of compound **5** with ethyl acetate in the presence of sodium ethoxide gave the sodium salt of 7amino-9-hydroxy-6*H*-benzo[*c*]chromen-6-one (**11**) as intermediate product which upon treatment with **8** in acetic acid and sodium acetate gave 7-((6,8-dichloro-4-oxo-4Hchromen-3-yl)methyleneamino)-9-hydroxy-6*H*-benzo[*c*]chromen-6-one (**12**) (Scheme 7).



Scheme 7

3.2. Molecular orbital calculations

The experimental IR frequencies of C=O groups of coumarin derivatives were compared with theoretical bond lengths of C=O groups which were obtained from molecular mechanical calculations on the basis of the semi-empirical AM1 and Ab Initio (STO-3G) methods of HyperChem 8.03 computer program after geometrical optimization of the structures for compounds (**2-12**) (Table 2).

Table 2. Calculated bond lengths of C=O of coumarin derivatives by semiempirical AM1 and Ab Initio (STO-3G) methods and their experimental IR $v_{C=0}$ values for compounds (**2a-12**).

	Bond lengths of C	Experimental				
Compound	Semi-empirical (AM1)	Ab Initio (STO-3G)	$v_{C=0}$ (cm ⁻¹)			
2a	1.22484 ^a	1.21413	1736			
2a	1.2303 ^b	1.21421	1682			
5	1.228 ^a	1.217	1723			
6a	1.22623 ^a	1.21621	1705			
6a	1.2309 ^b	1.21456	1680			
7	1.2353c	1.2208	1724			
9	1.22853 ^a	1.21732	1727			
9	1.23831 ^b	1.44367	1652			
12	1.22777 ^a	1.21652	1716			
12	1.23908 ^b	1.45056	1653			
r ^d	0.914	0.987	-			

^a C=O_{coumarin}

^b C=O_{chromone} or cyclic ketone

c C=Oquinolinone

^d *r* = regression coefficient.

The calculated bond lengths of C=O groups (Å) on the basis of semi-empirical AM1 method are linearly related to the measured IR $v_{C=0}$ groups (cm⁻¹) for compounds (**2-12**) and from the linear relation bond length (C=O) = 1.47-0.001 $v_{C=0}$, r = 0.9140 except (7), where r is regression coefficient. The negative slope reveals indirect proportionality of the calculated bond lengths with measured $v_{C=0}$ values, which agreement with Hooke's law and these support the proposed structures for the prepared compounds. On the other hand, when Ab Initio (STO-SG) method was used, the linear relation bond length (C=O) = $1.11+6.25 \times 10^{-5} v_{C=0}$, r = 0.9870 except (**2a**, **7**, **9b** and **12b**) which is less efficient method than the last method.

Also, the calculated net carbon charges by semi-empirical AM1 and Ab Initio (STO-3G) methods after geometrical optimization were compared with experimental ¹³C NMR δ values for compound 5 (Table 3).

The calculated net carbon charges on the basis of semiempirical AM1 method are linearly related to the experimental ¹³C NMR (δ in ppm) for compound **5** and from the linear relation charges on carbon atoms = -0.74 + 0.005 ¹³C NMR, r = 0.9200, except (C-2 and C-10), where r is regression coefficient. The positive slope reveals direct proportionality of the calculated net carbon charges with measured ¹³C NMR δ values, which support the proposed structure for compound **5**. Also, when Ab Initio (STO-3G) method was used, the linear relation charges on carbon atoms = -0.25 + 0.002 ¹³C NMR, r = 0.8340, except (C-2 and C-9), which less agreement with experimental data than semi-empirical AM1 method. The dependence of ¹³C NMR shifts on the net carbon charges for compound **5** is more pronounced than that found of IR ($v_{C=0}$) and their bond lengths for compounds (**2-12**), as indicated from slope values of semi-empirical AM1 method.

Table 3. Calculated net carbon charges by semi-empirical AM1 and Ab Initio (STO-3G) methods and their experimental ^{13}C NMR values for compound 5.

Carbon	Calculated net c	Experimental				
number	Semi-empirical (AM1)	Ab Initio (STO-3G)	¹³ C NMR δ (ppm)			
C-2	0.350	0.319	164.24			
C-3	-0.125	-0.042	118.66			
C-4	0.098	0.066	153.25			
C-5	-0.067	-0.048	135.86			
C-6	-0.159	-0.070	117.54			
C-7	-0.073	-0.043	127.69			
C-8	-0.150	-0.075	125.89			
C-9a	-0.153	-0.036	101.85			
C-10a	0.118	0.142	157.32			
C-9	-0.086	0.073	114.80			
C-10	-0.210	-0.189	18.79			
r*	0.920	0.834	-			

*r = regression coefficient.

3.3. Antimicrobial activity

The newly synthesized compounds were screened against Gram-positive bacteria: *Staphylococcus aureus* (ATCC 25923) and *Bacillus subtilis* (ATCC 6635), Gram-negative bacteria: *Salmonella typhimurium* (ATCC 14028) and *Escherichia coli* (ATCC 25922), Yeast: *Candida albicans* (ATCC 10231) and Fungus: *Aspergillus fumigatus*. The standardized disc-agar diffusion method [11] was followed to determine the activity of the synthesized compounds against the tested microorganisms.

Compound **12** showed high activities against *Aspergillus fumigates* at concentration of 2 mg and 1 mg, while it showed intermediate activities against *Bacillus subtilis, Escherichia coli* and *Candida albicans.* Compound **9** showed intermediate activities against *Bacillus subtilis, Escherichia coli* and *Candida albicans* (Table 4).

Table 4. Antimicrobial activities data of compounds 2-12.

	Mean of zone diameter ^a , mm											
	Gram-positive bacteria			Gram-negative bacteria			Yeasts ^b					
Sample	Staphylococcus aureus (ATCC 25923)		Bacillus subtilis (ATCC 6635)		Salmonella typhimurium (ATCC 14028)		Escherichia coli (ATCC 25922)		Candida Albicans (ATCC 10231)		Aspergillus fumigatus	
Conc. ^g	2	1	2	1	2	1	2	1	2	1	2	1
2	4 Ld	2 L	3 L	-c	2 L	-	4 L	2 L	2 L	-	-	-
5	3 L	2 L	3 L	-	2 L	-	2 L	-	7 L	4 L	-	-
7	-	-	6 L	4 L	-	-	3 L	-	9 L	5 L	2 L	-
6	-	-	6 L	4 L	-	-	3 L	-	9 L	5 L	2 L	-
9	8 L	5 L	15 Ie	11 I	-	-	18 I	12 I	18 I	13 I	8 L	5 L
12	6 L	3 L	13 I	9 L	4 L	-	17 I	12 I	20 I	17 I	28 H ^f	20 H
Control ^h	42	28	38	30	36	25	38	30	40	28	40	31

^a Calculate from 3 values.

^b Identified on the basis of routine cultural, morphological and microscopical characteristics.

c -: No effect.

^d L: Low activity = Mean of zone diameter $\leq 1/3$ of mean zone diameter of control.

e I: Intermediate activity = Mean of zone diameter ≤ 2/3 of mean zone diameter of control.

^rH: High activity = Mean of zone diameter > 2/3 of mean zone diameter of control.

g Concentration, mg/mL.

h Chloramphencol in the case of Gram-positive bacteria, Cephalothin in the case of Gram-negative bacteria and cycloheximide in the case of fungi.

4. Conclusion

The Claisen condensation of 2-hydroxaceophenone derivatives with ethyl cyanoacetate gave condensation and cyclocondensation products with different nucleophilic reagents and depends on the reactivity of 2-hydroxy-acetophenone, nucleophilic reagents, and the thermodynamic stabilities of the products. Also, the antimicrobial activities for the prepared compounds indicated that when coumarin derivatives bear a chromone moiety, the biological activities are increased compared with other prepared derivatives.

References

- [1]. El-Sayed, A. M.; Abdallah, O. A. Phosphorus Sulfur 2001, 170, 75-86.
- [2]. Periers, A. M.; Laurin, P.; Benedetti, Y.; Lachaud, S.; Ferroud, D.; Iltis, A.; Haesslein, J. L.; Klich, M.; LHermite, G.; Musicki, B. *Tetrahedron Lett.* 2000, 41(6), 867-871.
- [3]. Ali, T. E.; Abdel-Aziz, S. A.; El-Shaaer, H. M.; Hanafy, F. I.; El-Fauomy, A. Z. Phosphorus Sulfur 2008, 183, 2139-2160
- [4]. Ali, T. E.; Abdel- Aziz, S. A.; El-Shaaer, H. M.; Hanafy, F. I.; El-Fauomy, A. Z. Turk J. Chem. 2008, 32, 365-374.
- [5] El-Shaaer, H. M.; Foltinova, P.; Lacova, M.; Chovancova, J.; Stankovicova, H. Farmaco 1998, 53, 224-232
- [6]. Gasparova, R.; Lacova, M.; El-Shaaer, H. M.; Odlerova, Z. Il Farmaco 1997, 52, 251-253.
- [7]. Edwards, A. M.; Howell, J. B. L. Clin. Experim. Allergy 2000, 30, 756-774.
- [8]. Ishar, M. P. S.; Singh, G.; Singh, S.; Sreenivasan, K. K.; Singh, G. Bioorg. Med. Chem. Lett. 2006, 16, 1366-1370.
- [9]. Liu, J.; Wu, J.; Zhao, Y. X.; Deng, Y. Y.; Mei, W. L.; Dai, H. F. Chin. Chem. Lett. 2008, 19, 934-936.
- [10]. Nawrot-Modranka, J.; Nawrot, E.; Graczyk, J. Eur. J. Med. Chem. 2006, 41, 1301-1309.
- [11]. Mao, P. C. M.; Mouscadet, J. F.; Leh, H.; Auclair, C.; Hsu, L. Y. Chem. Pharm. Bull. 2002, 50, 1634-1637
- [12]. Kirkiacharian, S.; Thuy, D. T.; Sicsic, S.; Bakhchinian, R.; Kurkijan, R.; Tonnaire, T. Il Farmaco 2002, 57, 703-708.
- [13]. Lacova, M.; Gasparova, R.; Kois, P.; Bohac, A.; El-Shaaer, H. M. Tetrahedron 2010, 66, 1410-1419.
- [14]. Gaplovsky, A.; Donovalova, J.; Lacova, M.; Mracnova, R.; El-Shaaer, H. M. J. Photoch. Photobio. A 2000, 136, 61-65.
- [15]. El-Shaaer, H. M.; Perjessy, A.; Zahradnik, P.; Lacova, M.; Sustekova, Z. Monatsh. Chem. 1993, 124, 539-548.
- [16]. Bauer, A. W.; Kirby, W. W. M.; Sherris, J. C.; Turck, M. Am. J. Clin. Path. 1966, 45, 493-496.